Telehealth startups worry DEA proposal will disrupt prescribing drugs that prevent overdoses

As the DEA continues to propose stricter regulations on telehealth-based opioid prescribing, telehealth companies say they are worried that the crackdown won't allow them to prescribe life-saving medications that can help prevent opioid overdoses, The Wall Street Journal reported April 4. 

During the pandemic, a waiver was issued that allowed telehealth companies to prescribe controlled substances such as buprenorphine to patients without seeing them for an in-person consultation. 

But, the Biden administration is now proposing a rule that will discontinue the ability for telemedicine prescribing of controlled substances where the patient has never had an in-person consultation.

Specifically, under the new rule, patients could receive a 30-day supply of buprenorphine without an in-person exam, but would then need an in-person consultation to continue to receive prescriptions via telehealth.  

The DEA is expected to release a draft of the new rule following its comment period. 

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like